Despite these associations between age-associated hormonal changes and MS, evidence for clinical benefits of oestrogen or testosterone supplementation in either sex is limited, and randomized controlled trials are required 33
The GLP-1 space is shaping up to be one of the most competitive (and lucrative) markets in pharma, with obesity and diabetes care at the center of global health priorities
GLP-1 receptor agonists are having a moment
Curr Pharm Des 20:11261135 Sikiri P, Petek M, Ruman R, Seiwerth S, Grabarevi Z, Rotkvi I, Turkovi B, Jagi V, Mildner B, Duvnjak M, Lang N, Danilovi Z, Cviko A, Kolega M, Sallmani A, Djai S, Bura M, Brki T, Bani M, Dodig M, Cori V, imievi V, Veljaca M, Erceg D, Jeek D, Simuni-Banek L, Skroza N, Buli K, Buljat G, Hanevaki M, Orihova V, Luinger D, Culig J, Separovi J, Marovi A, Mie S, Suchanek E, Matoz W, Perovi D, Gjurain M, Mikulandra S, Dernikovi K, Cuk V, Karakas I (1993) A new gastric juice peptide, BPC